论文部分内容阅读
作者根据以往研究结果(即诱导治疗中柔红霉素的剂量是成人急性淋巴细胞白血病的主要预后因素),设计了一个ALLVR589化疗方案,力求将白血病细胞在耐药前迅速杀灭,其特点是在诱导治疗方案VDLP中给予大剂量的柔红霉素(30mg/m~2·d×3d,每当骨髓恢复,中性粒细胞>1500/μl,血小板>15000/μl时,重复1次,共3次,使柔红霉素总剂量达270/m~2),缓解早期又立即给予大剂量阿糖胞苷,并且将预防中枢神经系统白血病和反复强化治疗作为常规,持续3年余。 作者将1989年～1996年连续60例初诊患者按此
Based on the results of previous studies (ie, the dose of daunorubicin in induction therapy is the major prognostic factor for adult acute lymphoblastic leukemia), the authors designed an ALLVR589 chemotherapy regimen that seeks to rapidly kill leukemic cells before drug resistance. A large dose of daunorubicin (30mg/m~2d x 3d) was given in the induction therapy VDLP. When the bone marrow recovered, the neutrophils were more than 1500/μl and the platelets were >15000/μl. A total of 3 times, the total dose of daunorubicin up to 270/m~2), early relief and immediately given a large dose of cytarabine, and the prevention of central nervous system leukemia and repeated intensive treatment as a routine, lasting more than 3 years. The author presses 60 consecutive patients who were newly diagnosed from 1989 to 1996